Developer docs
API playgroundTry for free, no card

Search company profiles

Mirna Therapeutics

Full company profile

uuid003gaeo

Namestring
Mirna Therapeutics
Websiteurl
mirnatherapeutics.com
Company typeenum
Private
Founded yearint
2007
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
miRNA oncology therapeutics, microRNA-based cancer drugs, oncology drug development, RNA-targeted therapies, tumor suppressor miRNA
Industry4 codes
1siRNA Therapeutics (gene silencing)
CodeHLAAADABPrimaryYes
2RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
CodeHLAAADAHPrimaryNo
3RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
CodeHLAAADAGPrimaryNo
4RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
CodeHLAAADAEPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Oncology Therapeutics
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mirna Therapeutics is a clinical-stage biotechnology company that researches and develops microRNA (miRNA)-directed human oncology therapies. The company's pipeline focuses on leveraging tumor-suppressor and oncogenic miRNA biology to create novel cancer treatment candidates, advancing candidates from discovery through preclinical and clinical development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1miRNA-directed oncology therapeutics pipeline
CategoryOncology Therapeutics
No data
Peers10 records
1BioNTech
TypeBroad incumbent
Description

BioNTech develops mRNA-based immunotherapies and oncology vaccines. It operates in the RNA therapeutics space with a parallel oncology focus, making it a broad incumbent peer for benchmarking RNA-platform companies.

2Regulus Therapeutics
TypeDirect peer
Description

Regulus was the most direct microRNA therapeutics peer, developing anti-miR and miR mimics in oncology and rare disease. It shares Mirna's miRNA mechanism of action and clinical-stage oncology focus, making it the closest historical comparable.

3Moderna
TypeBroad incumbent
Description

Moderna is the leading mRNA therapeutics company with oncology programs. While mRNA is mechanistically distinct from miRNA, both are RNA-therapeutics platforms addressing cancer, making Moderna a broad incumbent peer in the RNA-oncology category.

4Ionis Pharmaceuticals
TypeBroad incumbent
Description

Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, addressing similar gene-expression modulation in oncology and rare disease. It is a broader incumbent in the oligonucleotide therapeutics space that overlaps with Mirna's RNA-modality approach.

5Arrowhead Pharmaceuticals
TypeDirect peer
Description

Arrowhead develops RNAi-based therapeutics using targeted delivery systems (e.g., TRiM platform) for oncology and other indications. It is a direct small-RNA therapeutics peer working through gene-silencing mechanisms analogous to Mirna's miRNA approach.

6Arcturus Therapeutics
TypeEmerging player
Description

Arcturus develops RNA-based therapeutics, including self-amplifying mRNA and RNAi approaches, with both rare-disease and oncology programs. It is an emerging player in the broader RNA therapeutics category with partial mechanistic overlap to Mirna.

7Dicerna Pharmaceuticals
TypeDirect peer
Description

Dicerna developed GalNAc-conjugated RNAi (siRNA) therapeutics with a similar focus on liver and oncology indications. It is directly comparable as a small-RNA gene-silencing platform that was ultimately acquired by Novo Nordisk.

8Alnylam Pharmaceuticals
TypeBroad incumbent
Description

Alnylam is the leading commercial-stage RNAi (siRNA) therapeutics company, working through the same RISC-mediated gene-silencing pathway that microRNA therapeutics exploit. It anchors the small-RNA therapeutic space that Mirna operates in.

9EnGeneIC
TypeEmerging player
Description

EnGeneIC is a clinical-stage oncology biotech developing targeted nanocell-based RNAi delivery platforms for solid tumors. It represents an emerging delivery-enabled RNA therapeutics approach relevant to Mirna's miRNA oncology pipeline.

10miRagen Therapeutics (now Viridian Therapeutics)
TypeDirect peer
Description

miRagen was a clinical-stage microRNA-targeted therapeutics company focused on hematological and oncology indications. It was the most directly comparable miRNA-focused peer to Mirna Therapeutics and was acquired and renamed Viridian Therapeutics.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mirna Therapeutics

Oncology Therapeuticsmirnatherapeutics.com

Mirna Therapeutics firmographics

Firmographics
Name
Mirna Therapeutics
Website
https://mirnatherapeutics.com
Company type
Private
Founded year
2007
Headcount range
11–50 employees
Ownership category
akta.pro rank

Mirna Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro primary industry
siRNA Therapeutics (gene silencing) (HLAAADAB)
akta.pro secondary industries
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

  • MiRNA oncology therapeutics
  • MicroRNA-based cancer drugs
  • Oncology drug development
  • RNA-targeted therapies
  • Tumor suppressor miRNA

Where Mirna Therapeutics is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

Mirna Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Mirna Therapeutics product offering

Product offering

Core offering

Mirna Therapeutics is a clinical-stage biotechnology company that researches and develops microRNA (miRNA)-directed human oncology therapies. The company's pipeline focuses on leveraging tumor-suppressor and oncogenic miRNA biology to create novel cancer treatment candidates, advancing candidates from discovery through preclinical and clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • miRNA-directed oncology therapeutics pipeline

Companies that use Mirna Therapeutics

Customer profile

Ideal customer profiles1 record

Mirna Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Mirna Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: BioNTech develops mRNA-based immunotherapies and oncology vaccines. It operates in the RNA therapeutics space with a parallel oncology focus, making it a broad incumbent peer for benchmarking RNA-platform companies.
  • Moderna: Moderna is the leading mRNA therapeutics company with oncology programs. While mRNA is mechanistically distinct from miRNA, both are RNA-therapeutics platforms addressing cancer, making Moderna a broad incumbent peer in the RNA-oncology category.
  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, addressing similar gene-expression modulation in oncology and rare disease. It is a broader incumbent in the oligonucleotide therapeutics space that overlaps with Mirna's RNA-modality approach.
  • Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage RNAi (siRNA) therapeutics company, working through the same RISC-mediated gene-silencing pathway that microRNA therapeutics exploit. It anchors the small-RNA therapeutic space that Mirna operates in.

Direct peers

  • Regulus Therapeutics: Regulus was the most direct microRNA therapeutics peer, developing anti-miR and miR mimics in oncology and rare disease. It shares Mirna's miRNA mechanism of action and clinical-stage oncology focus, making it the closest historical comparable.
  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using targeted delivery systems (e.g., TRiM platform) for oncology and other indications. It is a direct small-RNA therapeutics peer working through gene-silencing mechanisms analogous to Mirna's miRNA approach.
  • Dicerna Pharmaceuticals: Dicerna developed GalNAc-conjugated RNAi (siRNA) therapeutics with a similar focus on liver and oncology indications. It is directly comparable as a small-RNA gene-silencing platform that was ultimately acquired by Novo Nordisk.
  • miRagen Therapeutics (now Viridian Therapeutics): miRagen was a clinical-stage microRNA-targeted therapeutics company focused on hematological and oncology indications. It was the most directly comparable miRNA-focused peer to Mirna Therapeutics and was acquired and renamed Viridian Therapeutics.

Emerging players

  • Arcturus Therapeutics: Arcturus develops RNA-based therapeutics, including self-amplifying mRNA and RNAi approaches, with both rare-disease and oncology programs. It is an emerging player in the broader RNA therapeutics category with partial mechanistic overlap to Mirna.
  • EnGeneIC: EnGeneIC is a clinical-stage oncology biotech developing targeted nanocell-based RNAi delivery platforms for solid tumors. It represents an emerging delivery-enabled RNA therapeutics approach relevant to Mirna's miRNA oncology pipeline.

Market position

Customer concentration

Mirna Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mirna Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Mirna Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mirna Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirna Therapeutics

What does Mirna Therapeutics do?

Mirna Therapeutics is a clinical-stage biotechnology company that researches and develops microRNA (miRNA)-directed human oncology therapies. The company's pipeline focuses on leveraging tumor-suppressor and oncogenic miRNA biology to create novel cancer treatment candidates, advancing candidates from discovery through preclinical and clinical development.

When was Mirna Therapeutics founded?

Mirna Therapeutics was founded in 2007. It employs 11 to 50 people.

Where is Mirna Therapeutics based?

Mirna Therapeutics is headquartered in Austin, United States, in the North America region.

Who are Mirna Therapeutics's main competitors?

Broad incumbents on record are BioNTech, Moderna, Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Direct peers are Regulus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals and miRagen Therapeutics (now Viridian Therapeutics). Emerging players are Arcturus Therapeutics and EnGeneIC.

Does Mirna Therapeutics have an API?

No public API is recorded for Mirna Therapeutics.

What industry is Mirna Therapeutics in?

Mirna Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMarina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 MimicMarina Biotech's partner Mirna Therapeutics presented interim Phase 1 data on MRX34, a microRNA-34 mimic, at the EORTC-NCI-AACR symposium. The data show a manageable safety profile with a maximum tolerated dose of 110 mg/m2, and dose escalation is ongoing for a daily dosing regimen. The study has treated nearly 100 patients with early signals of clinical activity.GlobeNewswireMarina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going TrialMirna Therapeutics enrolled the first patient in the hematologic malignancy cohort of its Phase 1 trial of MRX34, a microRNA mimic. The trial, initiated in April 2013, aims to establish the maximum tolerated dose and recommended Phase 2 dose. Marina Biotech could receive up to $60 million in milestone payments and royalties.GlobeNewswireMarina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34Mirna Therapeutics initiated a Phase 1 clinical trial of MRX34, a miRNA mimic for cancer, in patients with unresectable primary liver cancer or metastatic liver involvement. The trial will enroll up to 48 patients and follows a standard oncology design. Marina Biotech, the licensee's technology provider, expects to be the only company using its delivery platform in both single- and double-stranded oligonucleotide trials.GlobeNewswireMarina Biotech Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery PlatformMarina Biotech announced the USPTO issued a Notice of Allowance for patent application 10/505,107 covering its SMARTICLES lipid delivery technology. The patent protects a library of delivery compounds, including DiLA2 and SMARTICLES-based lipids, which are licensed to ProNAi and Mirna Therapeutics. The company is applying these technologies in preclinical programs and licensing collaborations.